




# PHARMACEUTICAL 2017

DURECT CORP  
Rank 216 of 292





# PHARMACEUTICAL 2017

DURECT CORP  
Rank 216 of 292



The relative strengths and weaknesses of DURECT CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DURECT CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 24% points. The greatest weakness of DURECT CORP is the variable Liabilities, Current, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is -41%, being 44% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	32,426
Cost of Goods Sold	0
Intangible Assets	6,399
Liabilities, Current	28,750
Liabilities, Non-Current	0
Other Assets	386
Other Compr. Net Income	11
Other Expenses	5,290
Other Liabilities	0
Other Net Income	-2,145
Other Revenues	14,025
Property and Equipment	1,297
Research and Development	29,274
Selling, General and Administrative Expense	11,825

Output Variable	Value in 1000 USD
Assets	40,508
Liabilities	28,750
Expenses	46,389
Revenues	14,025
Stockholders Equity	11,758
Net Income	-34,509
Comprehensive Net Income	-34,504
Economic Capital Ratio	-41%